A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia

PHASE2CompletedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

May 5, 2020

Primary Completion Date

August 12, 2020

Study Completion Date

August 12, 2020

Conditions
COVID-19 Pneumonia
Interventions
DRUG

Tociliuzumab

Participants will receive IV TCZ.

Trial Locations (24)

11203

SUNY Downstate Medical Center., Brooklyn

11418

Jamaica Hospital Medical Center, Jamaica

15212

Allegheny Health Network (Pittsburg PA), Pittsburgh

18103

Lehigh Valley Health Network, Allentown

19140

Temple University Hospital, Philadelphia

20007

Medstar Georgetown University Hospital, Washington D.C.

21201

University of Maryland, Baltimore

27157

Wake Forest University Health Sciences, Winston-Salem

29425

Medical University of South Carolina, Charleston

32224

Mayo Clinic, Jacksonville

43608

Mercy St. Vincent Medical Center, Toledo

44106

University Hospitals Cleveland Medical Center, Cleveland

60068

Advocate Lutheran General Hospital, Park Ridge

60453

Advocate Christ Medical Center, Oak Lawn

77030

Houston Methodist Hospital, Houston

Michael E. DeBakey VA Medical Center, Houston

77479

Houston Methodist Sugar Land Hospital, Sugar Land

85054

Mayo Clinic - Arizona, Phoenix

89502

Renown Institute for Heart & Vascular Health, Reno

90033

LAC + USC Medical Center, Los Angeles

USC Keck Medical Center of USC, Los Angeles

92835

St. Jude Medical Center, Fullerton

06856

Norwalk Hospital, Norwalk

07470

St Joseph's Regional Medical Center, Wayne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04363736 - A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter